Cargando…
Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
The common γ-chain cytokine interleukin-15 (IL-15) plays a significant role in regulating innate and adaptive lymphocyte homeostasis and can stimulate anti-tumor activity of leukocytes. We have previously shown that the circulating IL-15 in the plasma is the heterodimeric form (hetIL-15), produced u...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657354/ https://www.ncbi.nlm.nih.gov/pubmed/29402721 http://dx.doi.org/10.1016/j.cyto.2018.01.011 |
_version_ | 1783438785740013568 |
---|---|
author | Bergamaschi, Cristina Watson, Dionysios C. Valentin, Antonio Bear, Jenifer Peer, Cody J. Figg, William D. Felber, Barbara K. Pavlakis, George N. |
author_facet | Bergamaschi, Cristina Watson, Dionysios C. Valentin, Antonio Bear, Jenifer Peer, Cody J. Figg, William D. Felber, Barbara K. Pavlakis, George N. |
author_sort | Bergamaschi, Cristina |
collection | PubMed |
description | The common γ-chain cytokine interleukin-15 (IL-15) plays a significant role in regulating innate and adaptive lymphocyte homeostasis and can stimulate anti-tumor activity of leukocytes. We have previously shown that the circulating IL-15 in the plasma is the heterodimeric form (hetIL-15), produced upon co-expression of IL-15 and IL-15 Receptor alpha (IL-15Rα) polypeptides in the same cell, heterodimerization of the two chains and secretion. We investigated the pharmacokinetic and pharmacodynamic profile and toxicity of purified human hetIL-15 cytokine upon injection in rhesus macaques. We compared the effects of repeated hetIL-15 administration during a two-week dosing cycle, using different subcutaneous dosing schemata, i.e. fixed doses of 0.5, 5 and 50 μg/kg or a doubling step-dose scheme ranging from 2 to 64 μg/kg. Following a fixed-dose regimen, dose-dependent peak plasma IL-15 levels decreased significantly between the first and last injection. The trough plasma IL-15 levels measured at 48 h after injections were significantly higher after the first dose, compared to subsequent doses. In contrast, following the step-dose regimen, the systemic exposure increased by more than 1 log between the first injection given at 2 μg/kg and the last injection given at 64 μg/kg, and the trough levels were comparable after each injection. Blood lymphocyte cell count, proliferation, and plasma IL-18 levels peaked at day 8 when hetIL-15 was provided at fixed doses, and at the end of the cycle following a step-dose regimen, suggesting that sustained expansion of target cells requires increasing doses of cytokine. Macaques treated with a 50 μg/kg dose showed moderate and transient toxicity, including fever, signs of capillary leak syndrome and renal dysfunction. In contrast, these effects were mild or absent using the step-dose regimen. The results provide a new method of optimal administration of this homeostatic cytokine and may have applications for the delivery of other cytokines. |
format | Online Article Text |
id | pubmed-6657354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-66573542019-07-25 Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques Bergamaschi, Cristina Watson, Dionysios C. Valentin, Antonio Bear, Jenifer Peer, Cody J. Figg, William D. Felber, Barbara K. Pavlakis, George N. Cytokine Article The common γ-chain cytokine interleukin-15 (IL-15) plays a significant role in regulating innate and adaptive lymphocyte homeostasis and can stimulate anti-tumor activity of leukocytes. We have previously shown that the circulating IL-15 in the plasma is the heterodimeric form (hetIL-15), produced upon co-expression of IL-15 and IL-15 Receptor alpha (IL-15Rα) polypeptides in the same cell, heterodimerization of the two chains and secretion. We investigated the pharmacokinetic and pharmacodynamic profile and toxicity of purified human hetIL-15 cytokine upon injection in rhesus macaques. We compared the effects of repeated hetIL-15 administration during a two-week dosing cycle, using different subcutaneous dosing schemata, i.e. fixed doses of 0.5, 5 and 50 μg/kg or a doubling step-dose scheme ranging from 2 to 64 μg/kg. Following a fixed-dose regimen, dose-dependent peak plasma IL-15 levels decreased significantly between the first and last injection. The trough plasma IL-15 levels measured at 48 h after injections were significantly higher after the first dose, compared to subsequent doses. In contrast, following the step-dose regimen, the systemic exposure increased by more than 1 log between the first injection given at 2 μg/kg and the last injection given at 64 μg/kg, and the trough levels were comparable after each injection. Blood lymphocyte cell count, proliferation, and plasma IL-18 levels peaked at day 8 when hetIL-15 was provided at fixed doses, and at the end of the cycle following a step-dose regimen, suggesting that sustained expansion of target cells requires increasing doses of cytokine. Macaques treated with a 50 μg/kg dose showed moderate and transient toxicity, including fever, signs of capillary leak syndrome and renal dysfunction. In contrast, these effects were mild or absent using the step-dose regimen. The results provide a new method of optimal administration of this homeostatic cytokine and may have applications for the delivery of other cytokines. 2018-05-07 2018-08 /pmc/articles/PMC6657354/ /pubmed/29402721 http://dx.doi.org/10.1016/j.cyto.2018.01.011 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Bergamaschi, Cristina Watson, Dionysios C. Valentin, Antonio Bear, Jenifer Peer, Cody J. Figg, William D. Felber, Barbara K. Pavlakis, George N. Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
title | Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
title_full | Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
title_fullStr | Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
title_full_unstemmed | Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
title_short | Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
title_sort | optimized administration of hetil-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657354/ https://www.ncbi.nlm.nih.gov/pubmed/29402721 http://dx.doi.org/10.1016/j.cyto.2018.01.011 |
work_keys_str_mv | AT bergamaschicristina optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques AT watsondionysiosc optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques AT valentinantonio optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques AT bearjenifer optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques AT peercodyj optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques AT figgwilliamd optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques AT felberbarbarak optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques AT pavlakisgeorgen optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques |